Accelerated Radiation Treatment for Fast-Growing Non-Small Cell Lung Cancer
Tests a faster radiation schedule in adults with fast-growing non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer that grows fast (high-proliferation), who are planned to have radiotherapy to the chest.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Non-small cell lung cancer confirmed by tissue or cell tests, any stage. The care team plans radiotherapy to the chest, either to remove all of the disease or to ease symptoms.
- Biomarker or test result
- High-proliferation non-small cell lung cancer.
Main reasons for not taking part
- Small cell lung cancer
- Severe heart disease (NYHA class III or higher, uncontrolled heart rhythm problems, or heart attack in the past 6 months)
- Pregnant or breastfeeding women, or people who could have children and will not use effective contraception
- Taking part in another interventional trial at the same time
- Other conditions the investigator considers a reason not to enroll, such as severe mental illness
Read by machine on 13 November 2026.
Where in China
- 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhou, ChinaContact: Lu WangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT07823855
- Record updated
- 16 September 2026
- Original description
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).Read full original descriptionShow less
A Single-arm Phase I/II Clinical Study of Simultaneous Integrated Boost Accelerated Hyperfractionated Radiotherapy for High-proliferation Non-small Cell Lung Cancer
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).
Inclusion: Age ≥ 18 years, male or female; Histologically or cytologically confirmed high-proliferation non-small cell lung cancer (NSCLC); Assessed by a multidisciplinary team (MDT) and planned to receive thoracic radiotherapy (either curative or palliative), regardless of stage.
Exclusion: Concurrent participation in other interventional clinical trials; Severe cardiac disease (New York Heart Association [NYHA] functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months); Other conditions deemed by the investigator to make the patient unsuitable for enrollment (e.g., severe mental illness); Small cell histology; Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use effective contraceptive measures.